Abeona Therapeutics is a commercial-stage company selling ZEVASKYN, an FDA-approved gene-corrected skin-cell therapy for wounds in recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic blistering skin disease.
Abeona's case rests on ZEVASKYN, the first approved autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa. Net revenue rose 31% to $11.4 million in Q2, but low manufacturing yield or failed lot release has left two of 12 treatments without recognized revenue. The case depends on more centers treating more patients while manufacturing failures stay rare, and cash was $146.8 million at June 30.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: ZEVASKYN treatments and revenue keep growing
Does ZEVASKYN revenue keep growing as more treatment centers come online?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
ZEVASKYN revenue rose 31% in Q2; manufacturing yield and treatment-center pace now set the launch's speed
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Other cancers, Skin diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
5 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.